COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

被引：0
|
作者：
Chouaid, C. [1 ]
Bensimon, L. [2 ]
Millier, A. [3 ]
Clay, E. [3 ]
Insinga, R. [4 ]
Arunachalam, A. [4 ]
Khandelwal, A. [5 ]
Bachelot, Levy L. [2 ]
Levy, P. [6 ]
机构：
[1] Creteil Univ Hosp, Dept Chest Med, Creteil, France
[2] MSD France, Courbevoie 92, France
[3] Creat Ceut, Paris 75, France
[4] Merck & Co Inc, N Wales, PA USA
[5] Complete HEOR Solut, Gurgaon, India
[6] Univ Paris 09, PSL Res Univ, LEDA LEGOS, Paris, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN116
引用
收藏
页码：S458 / S458
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [2] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China
    Liu, Huiqin
    Wang, Ying
    He, Qi
    HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [3] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
  • [4] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Dong Ding
    Huabin Hu
    Mengting Liao
    Yin Shi
    Longjiang She
    Linli Yao
    Youwen Zhu
    Shan Zeng
    Jin Huang
    Advances in Therapy, 2020, 37 : 2116 - 2126
  • [5] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
    Huiqin Liu
    Ying Wang
    Qi He
    Health Economics Review, 12
  • [7] First-line pembrolizumab plus platinum-pemetrexed in metastatic non-small cell lung cancer: Clinical experience in a Spanish tertiary hospital
    Lombardero, Lara
    De Elejoste, Ibone
    Casas, Raquel
    Azcuna, Josune
    Ortega, Berezi
    Mohamed Lamin, Failah
    Jimenez Labaig, Pablo
    Rubio, Itziar
    Munoz Llarena, Alberto
    Azkona, Eider
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
    Huiqin Liu
    Ying Wang
    Qi He
    Health Economics Review, 13
  • [9] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China (vol 12, 66, 2022)
    Liu, Huiqin
    Wang, Ying
    He, Qi
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [10] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND
    Harding, T.
    Insinga, R.
    Dawson, H.
    Bates, B. E.
    Arunachalam, A.
    Vandormael, K.
    VALUE IN HEALTH, 2019, 22 : S473 - S473
12345